Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 113

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Toward the Rational Design of p53-Stabilizing Drugs: Probing the Surface of the Oncogenic Y220C Mutant

Basse, Nicolas, Kaar, Joel L., Settanni, Giovanni, Joerger, Andreas C., Rutherford, Trevor J., Fersht, Alan R.·2010·Chemistry & Biology
DOI 10.1016/j.chembiol.2009.12.011
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.chembiol.2009.12.011

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 51

  1. Bahar, 1997, Direct evaluation of thermal fluctuations in proteins using a single-parameter harmonic potential, Fold. Des., 2, 173, 10.1016/S1359-0278(97)00024-2 · DOI · Paper page
  2. Bahar, 1998, Correlation between native-state hydrogen exchange and cooperative residue fluctuations from a simple model, Biochemistry, 37, 1067, 10.1021/bi9720641 · DOI
  3. Bahar, 1999, Collective motions in HIV-1 reverse transcriptase: examination of flexibility and enzyme function, J. Mol. Biol., 285, 1023, 10.1006/jmbi.1998.2371 · DOI · Paper page
  4. Boeckler, 2008, Targeted rescue of a destabilized mutant of p53 by an in silico screened drug, Proc. Natl. Acad. Sci. USA, 105, 10360, 10.1073/pnas.0805326105 · DOI · Paper page
  5. Bohm, 2004, Fluorine in medicinal chemistry, ChemBioChem, 5, 637, 10.1002/cbic.200301023 · DOI · Paper page
  6. Brooks, 1983, Charmm—a program for macromolecular energy, minimization, and dynamics calculations, J. Comput. Chem., 4, 187, 10.1002/jcc.540040211 · DOI · Paper page
  7. Bullock, 2001, Rescuing the function of mutant p53, Nat. Rev. Cancer, 1, 68, 10.1038/35094077 · DOI · Paper page
  8. Bullock, 1997, Thermodynamic stability of wild-type and mutant p53 core domain, Proc. Natl. Acad. Sci. USA, 94, 14338, 10.1073/pnas.94.26.14338 · DOI · Paper page
  9. Bullock, 2000, Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy, Oncogene, 19, 1245, 10.1038/sj.onc.1203434 · DOI · Paper page
  10. Bykov, 2005, Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs, J. Biol. Chem., 280, 30384, 10.1074/jbc.M501664200 · DOI · Paper page
  11. Ciulli, 2007, Fragment-based approaches to enzyme inhibition, Curr. Opin. Biotechnol., 18, 489, 10.1016/j.copbio.2007.09.003 · DOI
  12. Congreve, 2003, A rule of three for fragment-based lead discovery?, Drug Discov. Today, 8, 876, 10.1016/S1359-6446(03)02831-9 · DOI · Paper page
  13. Das, 2008, High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations, Proc. Natl. Acad. Sci. USA, 105, 1466, 10.1073/pnas.0711209105 · DOI · Paper page
  14. Davis, 2007, MolProbity: all-atom contacts and structure validation for proteins and nucleic acids, Nucleic Acids Res., 35, W375, 10.1093/nar/gkm216 · DOI · Paper page
  15. Dennis, 2002, Computational mapping identifies the binding sites of organic solvents on proteins, Proc. Natl. Acad. Sci. USA, 99, 4290, 10.1073/pnas.062398499 · DOI
  16. Di Como, 1998, Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay, Oncogene, 16, 2527, 10.1038/sj.onc.1202041 · DOI · Paper page
  17. Erlanson, 2006, Fragment-based lead discovery: a chemical update, Curr. Opin. Biotechnol., 17, 643, 10.1016/j.copbio.2006.10.007 · DOI
  18. Evans, 2006, Scaling and assessment of data quality, Acta Crystallogr. D Biol. Crystallogr., 62, 72, 10.1107/S0907444905036693 · DOI · Paper page
  19. Foster, 1999, Pharmacological rescue of mutant p53 conformation and function, Science, 286, 2507, 10.1126/science.286.5449.2507 · DOI · Paper page
  20. Friedler, 2002, A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants, Proc. Natl. Acad. Sci. USA, 99, 937, 10.1073/pnas.241629998 · DOI · Paper page
  21. Friedler, 2003, Kinetic instability of p53 core domain mutants: implications for rescue by small molecules, J. Biol. Chem., 278, 24108, 10.1074/jbc.M302458200 · DOI · Paper page
  22. Guvench, 2009, Computational fragment-based binding site identification by ligand competitive saturation, PLoS Comput. Biol., 5, e1000435, 10.1371/journal.pcbi.1000435 · DOI · Paper page
  23. Hajduk, 2007, A decade of fragment-based drug design: strategic advances and lessons learned, Nat. Rev. Drug Discov., 6, 211, 10.1038/nrd2220 · DOI · Paper page
  24. Hajduk, 1997, NMR-based discovery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein, J. Med. Chem., 40, 3144, 10.1021/jm9703404 · DOI · Paper page
  25. Hajduk, 2005, Druggability indices for protein targets derived from NMR-based screening data, J. Med. Chem., 48, 2518, 10.1021/jm049131r · DOI · Paper page
  26. Hajduk, 2005, Predicting protein druggability, Drug Discov. Today, 10, 1675, 10.1016/S1359-6446(05)03624-X · DOI · Paper page
  27. Hann, 1995, The dominating effect of mutant p53, Nat. Genet., 9, 221, 10.1038/ng0395-221 · DOI
  28. Hess, 2008, GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation, J. Chem. Theory Comput., 4, 435, 10.1021/ct700301q · DOI · Paper page
  29. Hollstein, 1991, p53 mutations in human cancers, Science, 253, 49, 10.1126/science.1905840 · DOI · Paper page
  30. Horovitz, 1992, Co-operative interactions during protein folding, J. Mol. Biol., 224, 733, 10.1016/0022-2836(92)90557-Z · DOI
  31. Humphrey, 1996, VMD: Visual molecular dynamics, J. Mol. Graph., 14, 33, 10.1016/0263-7855(96)00018-5 · DOI · Paper page
  32. Interlandi, 2008, Characterization and further stabilization of designed ankyrin repeat proteins by combining molecular dynamics simulations and experiments, J. Mol. Biol., 375, 837, 10.1016/j.jmb.2007.09.042 · DOI
  33. Issaeva, 2003, Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide, Proc. Natl. Acad. Sci. USA, 100, 13303, 10.1073/pnas.1835733100 · DOI · Paper page
  34. Joerger, 2007, Structure-function-rescue: the diverse nature of common p53 cancer mutants, Oncogene, 26, 2226, 10.1038/sj.onc.1210291 · DOI · Paper page
  35. Joerger, 2008, Structural biology of the tumor suppressor p53, Annu. Rev. Biochem., 77, 557, 10.1146/annurev.biochem.77.060806.091238 · DOI · Paper page
  36. Joerger, 2004, Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations, J. Biol. Chem., 279, 1291, 10.1074/jbc.M309732200 · DOI · Paper page
  37. Joerger, 2006, Structural basis for understanding oncogenic p53 mutations and designing rescue drugs, Proc. Natl. Acad. Sci. USA, 103, 15056, 10.1073/pnas.0607286103 · DOI · Paper page
  38. Kitayner, 2006, Structural basis of DNA recognition by p53 tetramers, Mol. Cell, 22, 741, 10.1016/j.molcel.2006.05.015 · DOI · Paper page
  39. Leslie, 1999, Integration of macromolecular diffraction data, Acta Crystallogr. D Biol. Crystallogr., 55, 1696, 10.1107/S090744499900846X · DOI · Paper page
  40. Levine, 1991, The p53 tumour suppressor gene, Nature, 351, 453, 10.1038/351453a0 · DOI · Paper page
  41. Liepinsh, 1997, Organic solvents identify specific ligand binding sites on protein surfaces, Nat. Biotechnol., 15, 264, 10.1038/nbt0397-264 · DOI
  42. MacKerell, 1998, All-atom empirical potential for molecular modeling and dynamics studies of proteins, J. Phys. Chem. B, 102, 3586, 10.1021/jp973084f · DOI · Paper page
  43. Meyer, 2003, NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors, Angew. Chem. Int. Ed. Engl., 42, 864, 10.1002/anie.200390233 · DOI · Paper page
  44. Nikolova, 1998, Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability, Proc. Natl. Acad. Sci. USA, 95, 14675, 10.1073/pnas.95.25.14675 · DOI · Paper page
  45. North, 2002, Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1, Mol. Carcinog., 33, 181, 10.1002/mc.10038 · DOI
  46. Seco, 2009, Binding site detection and druggability index from first principles, J. Med. Chem., 52, 2363, 10.1021/jm801385d · DOI · Paper page
  47. Seeber, 2007, Wordom: a program for efficient analysis of molecular dynamics simulations, Bioinformatics, 23, 2625, 10.1093/bioinformatics/btm378 · DOI · Paper page
  48. Tobi, 2005, Structural changes involved in protein binding correlate with intrinsic motions of proteins in the unbound state, Proc. Natl. Acad. Sci. USA, 102, 18908, 10.1073/pnas.0507603102 · DOI · Paper page
  49. Turk, D. (1992). PhD thesis. Technische Universität München, Munich, Germany.
  50. Vousden, 2007, p53 in health and disease, Nat. Rev. Mol. Cell Biol., 8, 275, 10.1038/nrm2147 · DOI · Paper page
  51. Yang, 2006, oGNM: online computation of structural dynamics using the Gaussian Network Model, Nucleic Acids Res., 34, W24, 10.1093/nar/gkl084 · DOI

Cited by

See all 113

Metadata

Authors
Basse, N., Kaar, J. L., Settanni, G., Joerger, A. C., Rutherford, T. J., & Fersht, A. R.
Venue
Chemistry & Biology
Publisher
Elsevier BV
Published
2010-01
Volume
17
Issue
1
Pages
46-56
ISSN
1074-5521
DOI
10.1016/j.chembiol.2009.12.011
Cited by
113
References
7
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Toward the Rational Design of p53-Stabilizing Drugs: Probing the Surface of the Oncogenic Y220C Mutant. https://app.cochat.ai/papers/10.1016/j.chembiol.2009.12.011
The paper
Basse, N., Kaar, J. L., Settanni, G., Joerger, A. C., Rutherford, T. J., & Fersht, A. R. (2010). Toward the Rational Design of p53-Stabilizing Drugs: Probing the Surface of the Oncogenic Y220C Mutant. Chemistry & Biology. https://doi.org/10.1016/j.chembiol.2009.12.011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.